{"id":"ddb7f1a7-9775-5f56-9824-becdcb4d8d3b","stable_key":"f8641d02-8413-5bd8-92e9-62ad49286e81:asa-megakaryocyte-cox1","predicate":"produces","statement":"In human megakaryocytic cell lines a single 10 micromolar aspirin exposure suppressed thromboxane B2 by 90% and 85% respectively with full recovery within 48 to 72 hours, selective cyclooxygenase-1 inhibition by SC-560 reduced thromboxane B2 by more than 75% whereas cyclooxygenase-2 inhibition by NS-398 had minimal effect, and repeated exposure every 24 hours produced concentration- and time-dependent suppression reaching 89% by day 2 at 1 micromolar and 73% by day 4 at 0.1 micromolar, with delayed recovery likely reflecting de novo synthesis of cyclooxygenase-1 protein.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"495d8108-cb0d-59ea-9389-5f07d59da817","mechanism_event_label":"The precursor cell makes its thromboxane with the first enzyme, and has to build new enzyme to recover.","subject":{"id":"6284d26c-01e2-5e12-b192-ee391dd107e2","slug":"ptgs1","display_name":"Cyclooxygenase-1 (PTGS1)","entity_type_key":"protein"},"object":{"id":"2551eb9f-8da1-5ab5-b132-cd2116b19271","slug":"thromboxane-a2","display_name":"Thromboxane A2","entity_type_key":"small_molecule"},"evidence_count":1,"mechanism_event":{"id":"495d8108-cb0d-59ea-9389-5f07d59da817","stable_key":"f8641d02-8413-5bd8-92e9-62ad49286e81:asa-megakaryocyte-cox1-event","event_type":"biochemical_relationship","label":"The precursor cell makes its thromboxane with the first enzyme, and has to build new enzyme to recover.","description":"In human megakaryocytic cell lines a single 10 micromolar aspirin exposure suppressed thromboxane B2 by 90% and 85% respectively with full recovery within 48 to 72 hours, selective cyclooxygenase-1 inhibition by SC-560 reduced thromboxane B2 by more than 75% whereas cyclooxygenase-2 inhibition by NS-398 had minimal effect, and repeated exposure every 24 hours produced concentration- and time-dependent suppression reaching 89% by day 2 at 1 micromolar and 73% by day 4 at 0.1 micromolar, with delayed recovery likely reflecting de novo synthesis of cyclooxygenase-1 protein.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"5ed63972-a09f-58b5-9df3-2bba73098850","slug":"megakaryocyte","display_name":"Megakaryocyte","entity_type_key":"cell_type"},"role":"host_cell","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"747a6bf8-1dda-55ae-8c6c-6f1da5d26661","slug":"sc-560","display_name":"SC-560, a selective COX-1 inhibitor","entity_type_key":"chemical_species"},"role":"isoform_probe","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"380910a2-ef0a-5d7d-b75a-0ec38b07c17f","slug":"ns-398","display_name":"NS-398, a selective COX-2 inhibitor","entity_type_key":"chemical_species"},"role":"isoform_probe","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"c8a31ed4-f2ca-5d43-8352-e9935129a785","slug":"ptgs2","display_name":"Cyclooxygenase-2 (PTGS2)","entity_type_key":"protein"},"role":"excluded_isoform","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"196e612b-08c7-509f-a4ad-5b98bb0eac69","slug":"platelet-cox-recovery","display_name":"Recovery of platelet cyclooxygenase activity after aspirin","entity_type_key":"cellular_process"},"role":"explained_process","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""},{"entity":{"id":"6284d26c-01e2-5e12-b192-ee391dd107e2","slug":"ptgs1","display_name":"Cyclooxygenase-1 (PTGS1)","entity_type_key":"protein"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":5,"notes":""},{"entity":{"id":"2551eb9f-8da1-5ab5-b132-cd2116b19271","slug":"thromboxane-a2","display_name":"Thromboxane A2","entity_type_key":"small_molecule"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":6,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/aspirin-research/41265381.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"88710110438cddd108a51822aeb63c5f0a8125192eecc85eeeaf1edf3c3d85cc\", \"start_char\": 0, \"end_char\": 2110, \"text_sha256\": \"88710110438cddd108a51822aeb63c5f0a8125192eecc85eeeaf1edf3c3d85cc\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Aspirin pharmacodynamics in MEG-01 and CHRF-288-11 human megakaryocytic cell lines with selective isoform inhibitors","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Single and repeated aspirin exposures from 0.1 to 10 micromolar, with SC-560 and NS-398 as isoform probes","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"A surrogate for a tissue that cannot ethically be sampled repeatedly. Cell lines rather than primary megakaryocytes, which the authors state.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Aspirin research collection; topical membership is not evidence of a direct clinical effect, and aspirin is recorded separately from salicylate, the metabolite it becomes.","comparator":null,"unit":null,"notes":"","entity":{"slug":"aspirin","display_name":"Aspirin / acetylsalicylic acid","entity_type_key":"drug"}},{"dimension":"organism","value_text":"Human cells","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The precursor cell makes its thromboxane with the first enzyme, and has to build new enzyme to recover.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[asa-p41265381] Aspirin inhibition and recovery of cyclooxygenase activity and thromboxane biosynthesis in human megakaryocytes: a translational surrogate model. (2025). https://pubmed.ncbi.nlm.nih.gov/41265381/ DOI: 10.1016/j.jpet.2025.103762","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Megakaryocytic cell lines","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"bb1de81b-7d11-5c33-b0d9-16b9c8a1ab44","evidence_kind":"source_excerpt","locator":"Lines 429-440","start_line":429,"end_line":440,"excerpt":"### asa-megakaryocyte-cox1\nIn human megakaryocytic cell lines a single 10 micromolar aspirin exposure suppressed thromboxane B2 by 90% and 85% respectively with full recovery within 48 to 72 hours, selective cyclooxygenase-1 inhibition by SC-560 reduced thromboxane B2 by more than 75% whereas cyclooxygenase-2 inhibition by NS-398 had minimal effect, and repeated exposure every 24 hours produced concentration- and time-dependent suppression reaching 89% by day 2 at 1 micromolar and 73% by day 4 at 0.1 micromolar, with delayed recovery likely reflecting de novo synthesis of cyclooxygenase-1 protein.\nCondition category: normal\nnutrient_topic: Aspirin research collection; topical membership is not evidence of a direct clinical effect, and aspirin is recorded separately from salicylate, the metabolite it becomes.\nplain_language: The precursor cell makes its thromboxane with the first enzyme, and has to build new enzyme to recover.\norganism: Human cells\ntissue_or_cell_type: Megakaryocytic cell lines\nexperimental_model: Aspirin pharmacodynamics in MEG-01 and CHRF-288-11 human megakaryocytic cell lines with selective isoform inhibitors\nlimitations: A surrogate for a tissue that cannot ethically be sampled repeatedly. Cell lines rather than primary megakaryocytes, which the authors state.\nexposure: Single and repeated aspirin exposures from 0.1 to 10 micromolar, with SC-560 and NS-398 as isoform probes\nevidence_span: {\"source_cache\": \"artifacts/aspirin-research/41265381.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"88710110438cddd108a51822aeb63c5f0a8125192eecc85eeeaf1edf3c3d85cc\", \"start_char\": 0, \"end_char\": 2110, \"text_sha256\": \"88710110438cddd108a51822aeb63c5f0a8125192eecc85eeeaf1edf3c3d85cc\"}\n[asa-p41265381] Aspirin inhibition and recovery of cyclooxygenase activity and thromboxane biosynthesis in human megakaryocytes: a translational surrogate model. (2025). https://pubmed.ncbi.nlm.nih.gov/41265381/ DOI: 10.1016/j.jpet.2025.103762","model_system":"Aspirin pharmacodynamics in MEG-01 and CHRF-288-11 human megakaryocytic cell lines with selective isoform inhibitors","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [asa-p41265381] Aspirin inhibition and recovery of cyclooxygenase activity and thromboxane biosynthesis in human megakaryocytes: a translational surrogate model. (2025). https://pubmed.ncbi.nlm.nih.gov/41265381/ DOI: 10.1016/j.jpet.2025.103762","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"712cf519-cd27-5a8b-9e2f-961a98d7a27e","stable_key":"import-f8641d02-8413-5bd8-92e9-62ad49286e81","title":"Aspirin: the serine it acetylates, the enzyme that acetylation creates, the dose that separates platelet from vessel wall, and the metabolite that is a different drug (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"93dd4343051c131e40d4fc3c95a978cd65478c13dcdb3f2d42507c49b09cb647","revision_id":"694e8ee7-49ca-5e6c-b58b-8ba8f82c2ad8","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}